These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38824816)

  • 41. Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma.
    Szentkereszty M; Ladányi A; Gálffy G; Tóvári J; Losonczy G
    Lung Cancer; 2024 Jun; 192():107824. PubMed ID: 38761665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
    Qin T; Xia J; Liu S; Wang J; Liu H; Zhang Y; Jia Y; Li K
    Thorac Cancer; 2020 May; 11(5):1139-1148. PubMed ID: 32154654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.
    Takada K; Okamoto T; Tominaga M; Teraishi K; Akamine T; Takamori S; Katsura M; Toyokawa G; Shoji F; Okamoto M; Oda Y; Hoshino T; Maehara Y
    PLoS One; 2017; 12(7):e0181598. PubMed ID: 28727766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus.
    Schoemmel M; Loeser H; Kraemer M; Wagener-Ryczek S; Hillmer A; Bruns C; Thelen M; Schröder W; Zander T; Lechner A; Buettner R; Schlösser H; Gebauer F; Quaas A;
    Clin Transl Oncol; 2021 Aug; 23(8):1601-1610. PubMed ID: 33566304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival.
    Pocha K; Mock A; Rapp C; Dettling S; Warta R; Geisenberger C; Jungk C; Martins LR; Grabe N; Reuss D; Debus J; von Deimling A; Abdollahi A; Unterberg A; Herold-Mende CC
    Clin Cancer Res; 2020 May; 26(9):2231-2243. PubMed ID: 31953311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
    Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic biomarker tumor-infiltrating lymphocytes failed to serve as a predictive biomarker for postoperative radiotherapy in completely resected pN2 non-small cell lung cancer: a retrospective analysis.
    Li J; Li L; Wang J; Liu N; Liu H; Xu F; Li M; Yuan S
    Respir Res; 2024 Jun; 25(1):244. PubMed ID: 38886760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
    Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
    Toyokawa G; Takada K; Tagawa T; Hamamoto R; Yamada Y; Shimokawa M; Oda Y; Maehara Y
    Ann Thorac Surg; 2019 Feb; 107(2):393-400. PubMed ID: 30343006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data.
    Ashok Kumar P; Karimi M; Basnet A; Seymour L; Kratzke R; Brambilla E; Le-Chevalier T; Soria JC; Olaussen KA; Devarakonda S; Govindan R; Tsao MS; Shepherd FA; Michiels S; Graziano S
    Clin Lung Cancer; 2023 Sep; 24(6):528-540. PubMed ID: 37438216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
    Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
    Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
    Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
    Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 57. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.
    Reiniger L; Téglási V; Pipek O; Rojkó L; Glasz T; Vágvölgyi A; Kovalszky I; Gyulai M; Lohinai Z; Rásó E; Tímár J; Döme B; Szállási Z; Moldvay J
    Acta Oncol; 2019 Aug; 58(8):1087-1094. PubMed ID: 31002007
    [No Abstract]   [Full Text] [Related]  

  • 58. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis.
    Giatromanolaki A; Koukourakis IM; Balaska K; Mitrakas AG; Harris AL; Koukourakis MI
    Med Oncol; 2019 Jul; 36(9):76. PubMed ID: 31342270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma.
    Kurbatov V; Balayev A; Saffarzadeh A; Heller DR; Boffa DJ; Blasberg JD; Lu J; Khan SA
    Ann Thorac Surg; 2020 Feb; 109(2):343-349. PubMed ID: 31568747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.
    Rocha P; Rodrigo M; Moliner L; Menendez S; Masfarré L; Navarro N; Del Rey-Vergara R; Galindo-Campos M; Taus Á; Giner M; Sanchez I; Rodríguez-Fuster A; Aguiló R; Chalela R; Sánchez-Font A; Belda J; Curull V; Pijuan L; Casadevall D; Clavé S; Bellosillo B; Perera-Bel J; Comerma L; Arriola E
    Lung Cancer; 2023 Jul; 181():107257. PubMed ID: 37263182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.